RLAY News and Press, Relay Therapeutics Inc. From 05/10/21

CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, today announced the appointment of Patri...

CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Bank of America 2021 Health Care Conference on Tuesday, May 11, 2021 at 8:45 a.m. ET. The fireside chat will be webcast live and may be access...

I operate two main portfolios: my "safe" portfolio and my high growth portfolio. This article will dissect and focus on my high-growth holdings. I generally like to invest in themes and tend to take a shotgun approach to my holdings in emerging sectors. I will list my holdings for 8 s...

CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, today announced the appointments of ...

Relay Therapeutics (RLAY) announces the acquisition of ZebiAI, a pioneer in applying massive experimental DNA encoded library data sets to power machine learning for drug discovery (ML-DEL).As per the terms, RLAY will pay $85M upfront, comprised of $20M in cash and $65M in RLAY common stock.Z...

Relay Therapeutics’ leadership in this new breed of biotech positions the company as a strategic partner of choice for emerging technologies and founders in these fields ZebiAI amplifies Relay Therapeutics’ Dynamo™ platform with a library of industry-leadi...

Relay Therapeutics (RLAY): FY GAAP EPS of -$5.40 misses by $0.96.Revenue of $82.65MCash, cash equivalents and marketable securities of $678.1M.Press Release For further details see: Relay Therapeutics EPS misses by $0.96

Advanced two programs, RLY-1971 and RLY-4008, into clinical development, and on track to initiate IND enabling studies with PI3Kα mutant selective inhibitor in 2021 Entered into a global collaboration with Genentech for the development and commercialization of RLY-197...

Finding the next Amazon is the holy grail and an epic quest for any growth oriented investor. The reality however is that the journey to that goal is primarily littered with shattered portfolios and broken dreams. I am taking a slightly different approach. By picking trends poised...

CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today announced that preclinical data for RLY-4008, a po...